Effects of Angiotensin II on human endothelial cells survival signalling pathways and its angiogenic response
Kou, Baijun, Vatish, Manu and Singer, Donald R. J.. (2007) Effects of Angiotensin II on human endothelial cells survival signalling pathways and its angiogenic response. Vascular Pharmacology, Vol.47 (No.4). pp. 199-208. ISSN 1537-1891Full text not available from this repository.
Official URL: http://dx.doi.org/10.1016/j.vph.2007.06.011
Reduced capillary density (rarefaction) is an early event of cardiovascular disease. The PI-3K-Akt pathway is a key player in anti-endothelial cells (ECs) apoptosis. VEGF is a key growth factor for angiogenesis. We investigated the effect of Angiotensin II (Ang II) on ECs survival signalling and angiogenesis in vitro. We found that Ang II had a biphasic effect on Akt phosphorylation by western blotting analysis. Low concentration Ang II caused a dose-dependent increase in Akt phosphorylation, while high concentration of Ang II led to a decrease of Akt phosphorylation. This effect was negative regulated by its type II receptor. Ang II 10(-4) M induced ECs apoptosis by its type H receptor was completely blocked by VEGF. Cell viability was increased by Ang II 10(-6) M and decreased by Ang II 10(-4) M. It was further decreased by pre-treatment with PI-3K/Akt inhibitor LY294002, but unaffected by p38-MAPK inhibitor SB202190. Ang II 10(-4) M reduced ECs' proliferation and vascular tube length, which were in part regulated by type II receptor. Our findings support a dose-dependent role of Ang II in effect on ECs survival and angiogenesis by PI-3K/Akt pathway. The anti-angiogenic effect of Ang H was mediated by its type II receptor.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RS Pharmacy and materia medica|
|Divisions:||Faculty of Medicine > Warwick Medical School|
|Journal or Publication Title:||Vascular Pharmacology|
|Official Date:||October 2007|
|Number of Pages:||10|
|Page Range:||pp. 199-208|
|Access rights to Published version:||Restricted or Subscription Access|
Actions (login required)